Tokyo, Japan, Dec 27, 2005 - (JCN) - Daiichi Sankyo has announced that its wholly owned subsidiary Daiichi Pharmaceutical has won the lawsuit against Mylan Pharmaceuticals.
Specifically, the US Court of Appeals for the Federal Circuit has affirmed the validity of US patent (No. 5,053,407) on levofloxacin, a broad spectrum synthetic antibacterial agent held by Daiichi. Consequently, Mylain is prohibited from producing any generic version of levofloxacin until Daiichi's patent expires.
Currently, levofloxacin is marketed under the trade names of Cravit in Japan and Levaquin in the US.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group